This was reported in The Wall Street Journal Monday. There are always risks with new meds. Here is my original blog on the topic of new oral drugs (Beware the Piranha). It's important to note, though, that Gilenya has been pretty safe early on. http://00634ca.netsolhost.com/blog/?p=61
ZURICH (Dow Jones)--The sudden death of a 59-year-old patient in the U.S. who died after the first-time use of Novartis AG's (NVS) multiple-sclerosis pill Gilenya is raising questions over the drug's safety even as the novel medicine, which was approved a year ago, has generally been well tolerated by thousand of patients.
Novartis said a patient, who had received the first dose of Gilenya on November 22, died a day later. The person, Novartis said, had successfully completed six hours of post-dose observation without incident. Because Gilenya can slow the heart rate of patients, heart monitoring in a doctor's office is recommended.
The patient, whose identity wasn't revealed, had suffered for about a decade from multiple sclerosis, an autoimmune illness that affects the brain and spinal cord. Gilenya was approved in 2010. At the time, experts said that while the safety profile of the drug is acceptable, patients need to be aware that the drug can lower the heart rate, provoke a small decline in lung function and cause eye problems.
http://online.wsj.com/article/BT-CO-...13-709910.html
Novartis said a patient, who had received the first dose of Gilenya on November 22, died a day later. The person, Novartis said, had successfully completed six hours of post-dose observation without incident. Because Gilenya can slow the heart rate of patients, heart monitoring in a doctor's office is recommended.
The patient, whose identity wasn't revealed, had suffered for about a decade from multiple sclerosis, an autoimmune illness that affects the brain and spinal cord. Gilenya was approved in 2010. At the time, experts said that while the safety profile of the drug is acceptable, patients need to be aware that the drug can lower the heart rate, provoke a small decline in lung function and cause eye problems.
http://online.wsj.com/article/BT-CO-...13-709910.html
Comment